Brendan Smith
Stock Analyst at TD Cowen
(2.20)
# 2,809
Out of 5,012 analysts
7
Total ratings
60%
Success rate
8.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Initiates: Hold | $16 | $16.47 | -2.85% | 1 | Sep 30, 2025 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $16.09 | -37.85% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $65.20 | -0.31% | 2 | Aug 7, 2024 | |
| NVAX Novavax | Maintains: Hold | $5 → $10 | $8.90 | +12.36% | 1 | May 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $36.94 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $15.65 | - | 1 | Dec 5, 2022 |
Simulations Plus
Sep 30, 2025
Initiates: Hold
Price Target: $16
Current: $16.47
Upside: -2.85%
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $16.09
Upside: -37.85%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $65.20
Upside: -0.31%
Novavax
May 13, 2024
Maintains: Hold
Price Target: $5 → $10
Current: $8.90
Upside: +12.36%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $36.94
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $15.65
Upside: -